Denali Therapeutics Inc. Common Stock
Veridion Score
Composite trend over time
Why is DNLI moving today?
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for DNLI.
DNLI insider activity
Denali Therapeutics Inc. Common Stock
No multi-insider buying cluster in the last 90 days
Net buying: $39.1M across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-01-08 | 2026-01-06 | Schuth Alexander O. | Insider | sell | $16.50 | 17,218 | 282,828 | $284K | SEC Form 4 |
| 2026-01-08 | 2026-01-06 | Watts Ryan J. | Insider | sell | $16.50 | 35,198 | 296,833 | $581K | SEC Form 4 |
| 2025-12-15 | 2025-12-11 | BAKER JULIAN | Insider | buy | $17.49 | 2,095,191 | 25,996,310 | $36.6M | SEC Form 4 |
| 2025-12-15 | 2025-12-11 | BAKER JULIAN | Insider | buy | $17.49 | 190,523 | 2,335,469 | $3.3M | SEC Form 4 |
| 2025-08-14 | 2025-08-13 | Ho Carole | Insider | sell | $14.64 | 806 | 216,585 | $12K | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 3 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moDNLI contract awards, year to date.
Public federal awards linked to this ticker.
DNLI lobbying filings, year to date.
Registered lobbying filings matched to Denali Therapeutics Inc. Common Stock.